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Abstract
Nanoparticle vaccines were produced using layer-by-layer fabrication and incorporating respiratory syncytial virus
(RSV) G protein polypeptides comprising the CX3C chemokine motif. BALB/c mice immunized with G protein
nanoparticle vaccines produced a neutralizing antibody response that inhibited RSV replication in the lungs following
RSV challenge. ELISPOT analysis showed that G nanoparticle vaccinated mice had increased levels of RSV G
protein-specific IL-4 and IFN-γ secreting cells compared to controls following RSV challenge. Remarkably, RSV
challenge of G protein nanoparticle vaccinated mice resulted in increased RSV M2-specific IL-4 and IFN-γ secreting
T cells, and increased M2-specific H-2Kd-tetramer positive CD8+ T cells in the lungs compared to controls. Cell type
analysis showed vaccination was not associated with increased pulmonary eosinophilia following RSV challenge.
These results demonstrate that vaccination of mice with the RSV G protein nanoparticle vaccines induces a potent
neutralizing antibody response, increased G protein- and M2- specific T cell responses, and a reduction in RSV
disease pathogenesis.
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Introduction
Human respiratory syncytial virus (RSV) is an important viral
agent causing serious lower respiratory tract illness in infants,
the elderly, and those individuals with cardiopulmonary disease
or with impaired immune responses [1–4]. Natural infection
with RSV provides incomplete protection from reinfection and
disease as demonstrated by the recurrence of even severe
RSV infections throughout life [5,6]. Despite decades of effort
to develop safe and effective RSV vaccines none have been
successful. The first RSV candidate vaccine, a formalin-
inactivated alum-precipitated RSV (FI–RSV) preparation did
not confer protection and was associated with a greater risk of
serious disease with subsequent natural RSV infection [7,8].
Live attenuated and inactivated whole virus vaccine candidates
have also failed to protect as they were either insufficiently
attenuated or demonstrated the potential for enhanced
pulmonary disease upon subsequent RSV infection [9–13].
Subunit vaccines based on the RSV F protein isolated from
infected cell culture have been evaluated in adults, children
over 12 months of age, and in elderly, but despite being well
tolerated the F subunit vaccines were not sufficiently
immunogenic [14–19]. Evidence indicates that the RSV F
protein is important in inducing protective immunity [16,20], but
studies evaluating a BBG2Na vaccine (a fusion protein that
consists of the central conserved region of the RSV G protein
fused to the albumin binding domain of streptococcal protein G)
in combination with different adjuvants and by different routes
of administration have shown a role for RSV G protein in
protection against RSV [21–23]. Particulate vaccines e.g. virus-
like particles (VLPs), nanoparticles and virosomes have been
used as new vaccine strategies to potentiate immune response
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against RSV antigens and have shown promising results
[24–30]. A recent study using VLPs demonstrated that mice
immunized with VLPs carrying RSV F or G protein had higher
viral neutralizing antibodies in vitro and significantly decreased
lung virus loads in vivo after live RSV challenge. However,
RSV G protein VLPs showed better protective efficacy than
RSV F protein VLPs as determined by the level of virus load in
the lungs and morbidity post-challenge [31].
Despite the evidence that RSV G protein can induce
protective immunity, G protein has also been implicated in
disease pathogenesis [32–35]. One of the disease
mechanisms linked to G protein is CX3C chemokine mimicry
[36]. RSV G protein has similarities to fractalkine, the only
known CX3C chemokine, and has fractalkine-like leukocyte
chemotactic activity in vitro [36]. RSV G protein acts as a
fractalkine receptor antagonist modulating the immune
response to infection, and inhibiting fractalkine-mediated
responses including altering pulmonary trafficking of CX3CR1+
immune cells, and modifying the magnitude and cadence of
cytokine and chemokine expression [37,38]. Subunit
vaccination with G protein polypeptides spanning the central
conserved region of the G protein induces antibodies that block
G protein CX3C-CX3CR1 interaction and disease
pathogenesis mediated by RSV infection [39]. Mice vaccinated
with polypeptides containing the CX3C motif generate
antibodies that inhibit G protein CX3C-CX3CR1 binding and
chemotaxis, reduce lung virus titers, and prevent body weight
loss and pulmonary inflammation [39–41]. Thus, an RSV
vaccine that induces antibodies that block G protein CX3C-
CX3CR1 interaction should prevent modulation of immune and
inflammatory responses to RSV infection.
Particulate vaccines have been shown to induce potent
immune responses in the absence of conventional adjuvants
due to their recognition by immune cells, as particle structures
can simulate natural pathogens such as viruses and bacteria.
By incorporating well-defined antigenic epitopes in micro- and
nanoparticle constructs, investigators have demonstrated
improved immunogenicity of both B and T cell epitopes in a
number of model systems including ovalbumin [42], tumor
antigens [43,44], hepatitis B antigens [45], RSV antigens [46],
and malaria and influenza antigens [47]. The increased
potency of nanoparticle vaccine constructs has been attributed
to mechanisms including efficient phagocytosis of the particles,
cross-presentation, and activation of dendritic cells by
increased cytokine production and co-stimulatory marker
expression [48–50]. In this study, a novel nanoparticle
fabrication method (layer-by-layer deposition; LbL) is used to
construct synthetic nanoparticle vaccines that elicit potent
humoral and cellular immune responses [42]. LbL
nanoparticles produced by the sequential layering of oppositely
charged polyelectrolytes on a core substrate were designed to
carry one of three designed polypeptides comprising the CX3C
motif from the RSV G protein, i.e. GA2, GB1 or GCH17. The
results show that mice vaccinated with RSV G nanoparticle
vaccines containing the CX3C motif elicit potent antibody
responses that neutralize RSV, increase RSV G- and M2-
specific T cell responses after RSV challenge, and inhibit
pulmonary disease pathogenesis following RSV challenge.
These findings suggest that an RSV G protein nanoparticle
approach provides a safe and new pathway for producing next-
generation RSV vaccines that are effective and prevent RSV G




Specific-pathogen-free, 6-to-8 weeks old female BALB/cAnN
(H-2d) mice (National Cancer Institute, NCI) were used in all
experiments. Mice were housed in microisolator cages and
were fed sterilized water and food ad libitum. All experiments
were performed in accordance with the guidelines of the
University of Georgia Institutional Animal Care and Use
Committee (IACUC), with protocols approved by the University
of Georgia IACUC.
Virus infection
The A2 and B1 strains of RSV were propagated in Vero E6
cells (ATCC CRL-1586) as described [51]. Mice were
anesthetized by intraperitoneal administration of Avertin
(180-250 mg/kg; Sigma-Aldrich) and intranasally challenged
with 106 PFU of RSV A2 in serum-free Dulbecco modified
Eagle medium (DMEM; Hyclone, Thermo Scientific).
Peptide synthesis
Peptides spanning the G protein CX3C motif of the RSV
strains A2, CH 17 [52] and B1 were designed for vaccination
(Table 1). C-terminal amide peptides were synthesized on a
CEM, LibertyTM microwave assisted synthesizer using the
manufacturer’s standard synthesis protocols. Crude reduced
peptides were partially purified by C18 reversed phase HPLC,
correct molecular weight was confirmed by electrospray mass
spectrometry (ESMS), and then lyophilized. Oxidative refolding
was accomplished by dissolving the peptides at 2-5 mg/mL in
redox buffer (2.5 mM reduced glutathione, 2.5 mM oxidized
glutathione, 100 mM Tris pH 7.0) for 3h at room temperature
then at 4°C overnight. Folding was judged complete by a shift
to slightly shorter retention time on analytical HPLC. Following
a final HPLC purification step refolding was confirmed by a loss
of 4.0 (+/- 0.4) amu in the ESMS spectra relative to that of the
reduced peptide, as well as an absence of free thiol as
detected by DTNB (Ellman’s) assay. Correct disulfide bonding
was partially confirmed by ESMS of fragments generated from
a thermolysin digest [53] of the synthetic peptide (data not
shown). Peptides were aliquoted, lyophilized, and stored at
-20°C until use.
Nanoparticle fabrication and quality control
Nanoparticles were constructed as previously described [42]
on 50 nm diameter CaCO3 cores by alternately layering poly-l-
glutamic acid (PGA, negative charge) and poly-l-lysine (PLL,
positive charge) to build up a seven-layer film where the
designed peptide (DP) containing the RSV G protein CX3C
motif linked to a cationic sequence was added as the
outermost layer. The compositions of the films were
RSV G Nanoparticle Vaccine Mediates Protection
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determined by amino acid analysis (AAA) which showed that
comparable amounts of the three peptide components were
present in each batch (Table 2). Endotoxin levels were
measured using limulus amebocyte lysate (LAL) assay and
were found to be less than 0.1 EU/ug of G peptide. The
dispersity of the particle vaccines was monitored by dynamic
light scattering (DLS). Stepwise LbL steadily increases the
diameter of the particles several fold, from an apparent
diameter of about 150 nm for uncoated particles to about
400-500 nm for fully coated particles. Some particle
aggregation was detected in each batch with a second
population of particles in the 1500-2000 nm range.
Vaccination
LbL nanoparticles were suspended in phosphate buffered
saline (PBS; Hyclone, Thermo Scientific) and dispersed by
water bath sonication immediately prior to immunization. Doses
were adjusted to deliver either 50 µg DP/100 µL/mouse. Mice
were immunized without adjuvant subcutaneously (s.c.)
between the shoulder blades on day 0 and boosted on day 21
with the same dose of vaccine used during prime
immunization. The control groups received either 105 PFU of
live RSV A2 by intranasal instillation (positive control for
protection), 100 µL of PBS per injection (negative control) or 10
µg of purified RSV A2 G protein as previously described [36],
dissolved in PBS and emulsified with TiterMax® at a 1:1 ratio
per injection (positive control for disease enhancement). The
antisera from controls and nanoparticle-vaccinated mice were
collected at 21 days post boost immunization and stored at
-80°C until use.
Quantification of RSV G and F proteins in virus
preparation
Proteins in virus preparations were resolved in
polyacrylamide gels as previously described [36]. Silver
staining of proteins in the polyacrylamide gels was
accomplished as recommended by the manufacturer (Pierce).
For quantification of individual proteins in the polyacrylamide
gels, different concentrations of bovine serum albumin (BSA)
were electrophoresed in the same gel. A standard curve based
on the stain of the BSA was used to determine the
concentration of the glycoproteins in the virus. For Western
analysis, proteins in the polyacrylamide gels were transferred
to polyvinylidene difluoride (PVDF) membranes and detected in
the blots as previously described [36].
Indirect ELISA
RSV A2- and B1-specific IgG antibodies were detected by
ELISA using 96-well high binding plates (Corning, NY) coated
with 106 PFU/mL RSV A2 or B1 in 0.05 M carbonate-
bicarbonate buffer, pH 9.6. Sera were added to plates in serial
dilutions. RSV-specific antibodies were detected with
horseradish peroxidase (HRP) conjugated antibodies specific
for mouse IgG, mouse IgG1 or mouse IgG2a (Southern
Biotech) followed by addition of SureBlue TMB 1-Component
Microwell Peroxidase Substrate (KPL, Inc.) for 15 min.
Antibody titers were determined as the last sample dilution that
generated an OD450 reading of greater than 0.2.
RSV plaque inhibition assay
Sera obtained from vaccinated and naïve mice were heat-
inactivated at 56°C for 30 min, and serial two-fold dilutions
starting at a dilution of 1:20 were made in serum-free DMEM.
Equal volumes of serum dilutions and RSV A2 previously
titrated to yield 200 PFU/200 µL/ well of final mixture were
Table 1. Designed peptides carrying the CX3C chemokine mimic epitopea of RSV G protein.
Name Epitope Peptide sequence RSV strain
bGA2 169-198 NFVPCSICS NNPTCWAICKRIPNKKPGKKTK20Y A2
bGCH17 169-198 NFVPCSICS NNPTCWDICKRIPSKKPGKKT K20Y CH17
bGB1 169-198 NFVPCSICGNNQLCK S ICKTIPSNKPKKKPK20Y B1
a The location of the CX3C motif in the G protein is underlined.
b GenBank sequences used in this study: AAC14901 (RSV A2), NP_056862 (RSV B1) and AF065255 (NY/CH17/93).
doi: 10.1371/journal.pone.0074905.t001
Table 2. Quality control data for nanoparticle vaccines.
aDP name Concentration by dAAA g/ml at 1% solid suspension EndotoxinEU/μg aDP Avg. particle diameter by eDLS nm (number %)
 aDP bPLL cPGA  Population 1 Population 2
GA2 57 138 227 0.02 482 (87%) 1590 (13%)
GCH17 47 126 210 0.07 697 (100%)  
GB1 44 127 218 0.05 437 (82%) 1710 (18%)
a DP: designed peptide, b PLL: poly-l-lysine, c PGA: poly-l-glutamic acid, d AAA: amino acid analysis and e DLS: dynamic light scattering.
doi: 10.1371/journal.pone.0074905.t002
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incubated at 37°C and 5% CO2 for 1h. Confluent monolayers of
Vero E6 cells prepared in 24-well plates were infected with 200
µL/ well, in triplicate, of the serum-virus mixture. After virus
adsorption for 2h at 37°C, the cell monolayers were overlaid
with 2% methylcellulose media (DMEM, supplemented with 2%
fetal bovine serum and 2% methylcellulose). Plates were
incubated at 37°C and 5% CO2 for 5 days. The cells were then
fixed with ice-cold acetone: methanol (60:40) and incubated
with a mouse monoclonal antibody specific for RSV F protein
(clone 131-2A) followed by a secondary goat anti-mouse IgG
antibody conjugated to alkaline phosphatase (AP) (Invitrogen).
Plaques were developed using 200 µL/well of 1-Step TMNBT/
BCIP (Thermo Scientific) at room temperature for 15 min.
Plaques were counted using a dissecting microscope. Titers
were calculated from the averages of triplicate sample wells
and the reciprocal dilution of the sera completely inhibiting
infection was considered as neutralizing antibody titer.
Lung virus titers
RSV lung virus titers in vaccinated and control mice were
determined as previously described [51]. Briefly, lungs were
aseptically removed from mice at day 5 post-RSV A2 challenge
(106 PFU /mouse), and individual lung specimens were
homogenized at 4°C in 1 mL of serum-free DMEM/ high
glucose (Hyclone) by use of gentleMACS™ Dissociator
(Miltenyi Biotec). Samples were centrifuged for 10 min at 200
xg the supernatants were transferred to a new tube and used
immediately or stored at -80°C until they were assayed. For the
plaque assay, 10-fold serial dilutions of the lung homogenates
were added to 90% confluent Vero E6 cell monolayers.
Following adsorption for 1h at 37°C, cell monolayers were
overlaid with 2% methylcellulose media and incubated at 37°C
for 5 days. The plaques were enumerated by immunostaining
with monoclonal antibodies against RSV F protein (clone
131-2A) as described above.
Histopathological evaluation
Lungs from vaccinated mice were removed 5 days post
challenge, perfused with 10% buffered formalin through the
heart and trachea and fixed in 10% buffered formalin. The
sections were embedded in paraffin, cut in 5 µm-thick sections
and stained with hematoxylin and eosin. The sections were
evaluated by light microscopy. A histological score for each
lung was determined according to the following criteria: 0 = no
lung abnormality; 1= <10% of airways inflamed; 2= 10 -30% of
airways inflamed; 3= 30 -50% of airways inflamed and 4=
>50% of airways inflamed [54]. The slides were evaluated
without knowledge of the type of mouse or exposure to antigen.
The area covered by an eye piece grid was judged to be
normal or abnormal.
ELISPOT analysis
The day before the assay, 96-well Multiscreen plates
(Millipore) were coated with the anti-mouse IL-4 or anti-mouse
IFN-γ capture antibody (R&D Systems) and incubated
overnight at 4°C. The plates were then blocked by the addition
of 200 µL of RPMI-10 media (RPMI 1640 supplemented with
10% FBS, 100 U/mL penicillin, 100 µg/mL streptomycin, 50 µM
2-mercaptoethanol and 2 mM L-glutamine) and incubated for 2
h at 37°C. In parallel, spleens were harvested from vaccinated
and naïve mice at 5 days post challenge with RSV A2 and
prepared to a single cell suspension using a syringe plunger
and a 70 µm mesh nylon strainer. The cell suspensions were
collected by centrifugation for 10 min at 200 x g and suspended
in RPMI-10 at a concentration of 107 cells/mL. Spleen cell
suspensions were added to each well, and cells were
stimulated with either 5 µg/mL M282-90 (SYIGSINNI), 5 µg/mL
G183-197 (WAICKRIPNKKPGKK) or without peptide for 24h at
37°C and 5% CO2. Plates were washed 4 times with wash
buffer (0.05% Tween-20 in PBS), anti-mouse IL-4 or anti-
mouse IFN-γ detection antibody (R&D Systems) was added
and plates were incubated overnight at 4°C. Detection antibody
was removed, plates were washed and cytokine spots were
developed using ELISpot blue color module (R&D Systems).
Spots were counted using an ELISPOT reader (AID EliSpot
Reader System). RSV-specific ELISPOT numbers were
determined from triplicate wells/cell population by subtracting
the mean number of ELISPOTs in the unstimulated wells.
BAL collection and quantification of cytokines
Five days post-challenge, a subset of mice from each group
was sacrificed and tracheotomy was performed. The mouse
lungs were flushed three times with 1 ml of PBS and the
retained BAL was centrifuged at 400 x g for 5 min at 4°C. The
recovered supernatants were collected and stored at -80°C
until assessed for cytokine concentration, and the cell pellet
were resuspended in 200 µL of FACS staining buffer (PBS
containing 1% BSA). Total cell numbers were counted using a
hemocytometer. The Luminex® xMAP™ system using a
MILLIPLEX MAP mouse cytokine immunoassay
(MCYTOMAG-70K, Millipore) was used to quantitate cytokines
in BAL supernatants according to the manufacturer protocol.
Briefly, beads coupled with anti-IL-4, anti-IL-5, anti-IFN-γ, anti-
IL17A, anti-TNF-α and anti-IL-13 monoclonal antibodies were
sonicated, mixed, and diluted 1:50 in assay buffer. For the
assay, 25 µL of beads were were mixed with 25 µL of PBS, 25
µL of assay buffer and 25 µL of BAL supernatant and
incubated overnight at 4°C. After washing, beads were
incubated with biotinylated detection antibodies for 1 h and the
reaction mixture was then incubated with streptavidin-
phycoerythrin (PE) conjugate for 30 min at room temperature,
washed, and resuspended in PBS. The assay was analyzed on
a Luminex 200 instrument (Luminex Corporation, Austin, TX)
using Luminex xPONENT 3.1 software.
Flow cytometry
For flow cytometry analysis, cell suspensions were incubated
in FACS staining buffer and blocked with FcγIII/II receptor
antibody (BD), and subsequently stained with antibodies from
BD bioscience, i.e. PE-Cy7 or PE-conjugated anti-CD3e
(145-2C11), PerCP-Cy5.5 or FITC -conjugated anti-CD8α
(53-6.7), PerCP-Cy5.5-conjugated anti-CD4 (RM4-5) and
optimized concentration of APC-conjugated MHC class I H-2Kd
tetramer complexes bearing the peptide SYIGSINNI (Beckman
Coulter) representing the immunodominant epitope of the RSV
M2-1 protein [55]. To determine cell types in lungs, cell
RSV G Nanoparticle Vaccine Mediates Protection
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suspensions were stained for 30 min at 4°C with an optimized
concentration of PerCP-Cy5.5-conjugated anti-CD45 (30-F11),
FITC-conjugated anti-CD11c (HL3), or PE-conjugated anti-
SiglecF (E50-2440). Cells were acquired on a LSRII flow
cytometer (BD bioscience) with data analyzed using FlowJo
software (v 7.6.5). Based on cell surface markers expression
two different cell type were identified: CD45+SiglecF+ CD11clow
as eosinophils and CD45+SiglecF + CD11chigh as alveolar
macrophages [56].
Statistics
All statistical analyses were performed using GraphPad
software (San Diego, CA). Statistical significance was
determined using One-way ANOVA followed by Bonferroni’s
post-hoc comparisons tests, a p value < 0.05 was considered
significant.
Results
RSV G nanoparticle vaccination induces robust
antibody responses
Nanoparticle vaccines having a RSV G CX3C motif were
prepared as previously described [42] where each construct
consisted of seven base layers with the designed peptide (DP)
added as the eighth and outermost layer. Three nanoparticle
vaccines were generated containing different versions of the
CX3C motif: GA2 (CWAIC), GCH17 (CWDIC) and GB1
(CKSIC) (Table 1 and Figure S1). BALB/c mice were
subcutaneously immunized with 50 µg of GA2, GCH17 or GB1
nanoparticle vaccines in PBS where the dose was based on
the amount of designed peptide (DP) delivered. Control groups
were age- and sex-matched BALB/c mice that received live
RSV A2, PBS or purified RSV G protein. Twenty one days after
the second immunization (boost), mice were bled for
determination of antibody titers by ELISA using plates coated
with either RSV A2 or RSV B1. Immunization with GA2,
GCH17, RSV A2 G protein and live RSV A2 elicited high titers
of anti-RSV A2 IgG (Figure 1A and Figure S1) and lower but
significant (p<0.05) levels of cross-reactive anti-RSV B1 IgG
(Figure 1B). IgG levels induced by GA2 and GCH17 were
similar to antibody levels induced by purified G protein
combined with adjuvant indicating that nanoparticle vaccination
without adjuvant induces equivalent humoral responses.
Notably, immunization with the GB1 elicited lower antibody
titers that reacted against both homologous (RSV B1, Figure
1B) and heterologous (RSV A2, Figure 1A) virus with
equivalent potencies. Although both IgG1 (Figure 1C and 1D)
and IgG2a (Figure 1E and 1F) subtypes were generated in
response to each of the vaccines tested, only GA2 nanoparticle
vaccination induced an IgG2a response similar to live RSV A2
vaccination, and only GB1 induced a balanced IgG1/2a
response to RSV A2. Nevertheless, IgG1 was the main
subtype produced in mice vaccinated with nanoparticles. These
results demonstrate that vaccination with RSV G nanoparticles
vaccines in the absence of adjuvant can elicit a strong humoral
response comprising both IgG subtypes IgG1 and IgG2a.
Vaccination with RSV G nanoparticles induces
neutralizing antibodies
Neutralizing antibody is a critical component of an efficacious
vaccine. To determine whether vaccination with RSV G protein
nanoparticles induced neutralizing antibodies, an in vitro
plaque inhibition assay was performed using heat-inactivated
Figure 1.  Antibody responses elicited by vaccination with
RSV G protein nanoparticles.  Groups of BALB/c mice (n=5)
were vaccinated with nanoparticle vaccines diluted in PBS to
yield 50 µg of designed peptide per dose, with 10 µg of purified
G protein emulsified 1:1 with TiterMAX®, 105 PFU of live RSV
A2 or with 100 µL of PBS. Sera were obtained from blood
taken 21 days after the secondary inoculation. RSV A2 (A, C,
and E) and RSV B1 (B, D, and F)-specific IgG (A and B), IgG1
(C and D) and IgG2a (E and F) levels were determined by
indirect ELISA. Bars represent the average titer of each group
with error bars representing the SEM from n=5 mice per group.
*, #, p<0.05, significant difference as determined by one-way
ANOVA and Dunnett’s test, compared with PBS vaccinated
control mice (*) or compared to live RSV A2 vaccinated mice
(#).
doi: 10.1371/journal.pone.0074905.g001
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mouse sera from vaccinated or challenged mice (Figure 2).
Three weeks post-boost immunization, and prior to challenge,
mice vaccinated with live RSV A2, GA2 nanoparticles or
GCH17 nanoparticles showed a significant (p<0.05) increase in
neutralizing antibody titer compared to PBS vaccinated mice,
while neither GB1 nanoparticles nor G protein vaccinated mice
showed substantial increases in neutralization titer compared
to the PBS group (Figure 2). Five days post-RSV challenge,
the levels of serum neutralizing antibodies increased in all
groups, however only GA2 nanoparticle, G protein and live
RSV A2 vaccinated mice had antibody titers that were
significantly (p<0.05) higher than PBS vaccinated mice (Figure
2). Mice vaccinated with live RSV A2 developed the strongest
neutralizing antibody response, nevertheless, there was no
significant (p<0.05) difference between live RSV A2 and GA2
nanoparticle vaccinated mice indicating that antibodies specific
against the G protein CX3C motif induced by vaccination with
the GA2 nanoparticle can block RSV infection in vitro.
RSV G nanoparticle vaccination is protective against
challenge
To evaluate whether immunization with RSV G protein
nanoparticles induces protective immunity, vaccinated mice
were challenged with RSV A2 virus (106 PFU/mouse) at 6
weeks post-boost vaccination, and the lung virus loads
determined at day 5 post-challenge. All vaccinated groups
showed a significant (p<0.05) decrease in lung virus loads
compared with PBS control, however only mice vaccinated with
GA2 nanoparticle and live RSV A2 showed complete inhibition
of virus replication (Figure 3A). Importantly, mice immunized
with GB1 nanoparticles had reduced lung virus replication
indicating vaccination induced a level of cross-protection
against RSV A2 challenge. Overall, lung virus titer inversely
correlated with the neutralizing antibody titers (Figure 2 and
Figure 3A). To determine if vaccination increased disease
pathogenesis the percent body weight loss and lung
histophatological examination was determined. Mice
vaccinated with purified G protein and challenged with RSV A2
immediately lost weight with weight loss peaking at 21% on day
5 post-challenge and showed increased airway inflammation,
while mice vaccinated with live RSV, and G nanoparticles
developed minor airway inflammation (Figure 3C) and limited
weight loss peaking at 5-7% on day 3 post-challenge (Figure
3B). Importantly, G nanoparticle vaccinated mice began to
regain lost weight more quickly than the PBS vaccinated mice,
suggesting that vaccination with the G protein CX3C motif is
associated with improved disease outcome following RSV
challenge. These results demonstrate that vaccination with the
RSV G nanoparticles induce protective immunity against RSV
A2 without inducing increased disease pathogenesis.
Mice vaccinated with RSV G nanoparticles develop
Th1/Th2 memory responses
Previous studies have reported that vaccinating BALB/c mice
with RSV G protein can elicit a Th2-type biased CD4+ T cell
response upon RSV challenge, and that this skewed Th2-type
response is associated with aspects of disease pathogenesis
that include airway hyperresponsiveness, mucus over-
Figure 2.  RSV A2 neutralizing antibodies in mice vaccinated with RSV G protein nanoparticles.  Sera from vaccinated mice
were evaluated for neutralizing antibodies by plaque inhibition assay. Serum samples were collected 21 days after the secondary
inoculation (grey bars) and 5 days post challenge (black bars) with 106 PFU of RSV A2. Error bar represents the SEM from n=5
mice per group. *, #, p<0.05, significant difference as determined by one-way ANOVA and Dunnett’s test, compared with PBS
vaccinated control mice (*) or compared to live RSV A2 vaccinated mice (#).
doi: 10.1371/journal.pone.0074905.g002
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Figure 3.  Lung virus titers and body weight loss following
RSV A2 challenge of vaccinated mice.  Groups of BALB/c
mice were vaccinated with nanoparticle diluted in PBS to yield
50 µg of designed peptide per dose, with 10 µg of purified G
protein emulsified 1:1 with TiterMAX®, 105 PFU of live RSV A2
or with 100 µL of PBS on days 0 and 21, and challenged i.n. on
day 42 with 106 PFU of RSV A2. A) Lung virus titers were
determined 5 days post-challenge by plaque assay (n=5). The
data are presented as PFU/g of lung tissue. B) Animals were
weighed daily and percentage of weight loss calculated based
on day 0. C) Quantitation of lung inflammation at day 5 post
challenge (n=3). Error bar represents the SEM from n=3-5 mice
per group. *, #, p<0.05, significant difference as determined by
one-way ANOVA and Dunnett’s test, compared with PBS
vaccinated control mice (*) or compared to live RSV A2
vaccinated mice (#).
doi: 10.1371/journal.pone.0074905.g003
production, and pulmonary eosinophilia [57–59]. Thus, the
outcome of RSV G nanoparticle vaccination and induction of a
Th2-type biased T cell response following RSV challenge was
investigated. Accordingly, RSV G nanoparticle vaccinated mice
were intranasally challenged with RSV A2 at week 6 post-boost
and the Th1- (IFN-γ) and Th2-type (IL-4) cell frequencies were
measured by ELISPOT assay at day 5 post-challenge.
Compared to purified RSV G protein-vaccinated group, mice
immunized with GCH17 or GB1 nanoparticle vaccines had
lower frequencies of G- and M2-specific IL-4 secreting cells
than mice vaccinated with purified G protein, however this
difference was not statistically significant (Figure 4A), but
similar frequencies of G-specific IFN-γ- secreting cells (Figure
4B). Nevertheless, all vaccinated groups showed higher IL-4
frequencies than the PBS control group (Figure 4A).
Remarkably, mice vaccinated GA2 or GCH17 nanoparticle
vaccines had a significant (p<0.05) increase in the M2-specific
IFN-γ-expressing splenocytes compared to PBS vaccinated
mice, and similar to the group vaccinated with live RSV A2
(Figure 4B). Since the nanoparticle vaccines do not have any
RSV M2 peptide or related sequences, this finding shows that
G nanoparticle vaccination potentiates RSV M2-specific T
lymphocyte responses following RSV challenge. Taken
together, these results indicate that RSV G nanoparticle
vaccination induces strong Th1 and Th2 G protein-specific T
cell response.
Vaccination with RSV G nanoparticles potentiates M2-
specific CD8 T cell responses
To address features that may contribute to the increased M2-
specific IFNγ-secreting cell frequency in RSV G nanoparticle
vaccinated mice challenged with RSV (Figure 4B), spleen and
BAL leukocytes from these vaccinated mice were evaluated at
day 5 post-RSV A2 challenge, and the number of CD8+ T cells
positive for RSV M282-90 MHC class I H-2Kd tetramer
determined by flow cytometry. M2-specific CD8+ T cells in the
spleen were increased following challenge compared to
uninfected control mice regardless of prior vaccination (Figure
5B). Upon challenge mice vaccinated with G nanoparticles
showed an increase in the percentage of M2-specific CD8+ T
cells in the BAL that was comparable to vaccinated mice
having a recall CD8 T cell response to live RSV A2 (Figure 5A
and Figure S2); however, this increase was only statistically
significant for the GA2 and GCH17 groups (Figure 5A and 5C).
It is important to note that the increase was not linked to an
overall increase in the total pulmonary CD8+ T cell population
(Figure 6A). These results show that vaccination with
nanoparticles carrying the central conserve region of the RSV
G protein is associated with increased pulmonary recruitment
of RSV M2-specific CD8+ T cells following RSV challenge. A
possible explanation for this outcome is that the immune
response against the RSV G CX3C motif induced by
vaccination prevents G protein-mediated immune modulation of
the CD8+ T cell response to RSV infection [37,38] driving a
more potent Th1-type and CD8+ T cell response to RSV M2 at
the site of viral infection.
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Mice vaccinated with RSV G nanoparticles are
protected against RSV disease
Previous studies have shown that the magnitude of weight
loss correlates with cell recruitment to the lung compartment
[32,60,61]. We found that mice vaccinated with G nanoparticles
had reduced weight loss and reduced airway inflammation
Figure 4.  Frequency of RSV-specific IFNγ and IL-4
secreting cells after virus challenge.  The number of G183-
specific (grey bars) and M282-specific (black bars) IL-4 (A) or
IFNγ (B) producing splenocytes was determined by ELISPOT
in cells harvested 5 days post-challenge. The data are
presented as cytokine spots/106 splenocytes. Error bars
represent the SEM from n=5 mice per group. *, #, p<0.05,
significant difference as determined by one-way ANOVA and
Dunnett’s test, compared with PBS vaccinated control mice (*)
or compared to live RSV A2 vaccinated mice (#).
doi: 10.1371/journal.pone.0074905.g004
(Figure 3), then to corroborate that vaccination with these
nanoparticles was not inducing enhanced disease upon RSV
challenge, BAL was evaluated for cell recruitment and
cytokines at day 5 post-RSV A2 infection. Mice vaccinated with
G nanoparticles had similar numbers of CD4+ and CD8+ T cells
(Figure 6A) in the BAL compared to mice vaccinated with live
RSV A2, but lower CD4+ T cells numbers than G protein
vaccinated mice (Figure 6A). There was no significant increase
in pulmonary macrophages in any of the vaccinated groups
(Figure 6B). Consistent with previous reports [51,57,58],
vaccination with purified G protein induced increased lung
eosinophilia upon RSV infection compared to PBS control, or
importantly, G nanoparticle vaccinated mice (Figure 6B).
Concordantly, analysis of cytokines in BAL fluid showed that
the Th1-type cytokine, IFNγ, was increased in all groups upon
challenge being significantly (p<0.05) higher in mice vaccinated
with G protein (Figure 6C). The Th2-type cytokines IL-4, IL-5
and IL-13 were low in all groups except for mice vaccinated
with purified G protein (Figure 6C). Levels of IL-17A and TNF-α
were also low in all vaccinated groups except for mice
vaccinated with G protein (Figure 6C). Overall, these findings
correlate with the histophatological data (Figure 3C) and the
granulocyte analysis (Figure 6B) and demonstrate that G
protein polypeptide nanoparticle vaccines having the CX3C
motif induce a safe and effective immune response similar to
that induced by live RSV A2 vaccination, and importantly,
protect against RSV disease pathogenesis.
Discussion
Both humoral and cellular immunity contribute to the host
defense against RSV infection [62,63], where neutralizing
antibodies are the primary means of protecting against
infection, while cell-mediated responses appear to have greater
importance for virus clearance [64]. Among RSV antigens, the
F protein has been shown to induce neutralizing antibodies and
protective immunity in humans and various animal models
[65,66]. RSV G has also been shown to induce neutralizing and
protective immunity, but to lesser efficiency than F protein
[21,67]. However, mixtures of anti-G protein monoclonal
antibodies specific for non-overlapping epitopes across the G
protein have been shown to be neutralizing due to their
synergistic effect, suggesting that polyclonal anti-G protein
antibodies can effectively neutralize RSV most likely by steric
hindrance that prevents virus binding to the host cell
membrane [68]. Importantly, vaccination to induce anti-G
protein antibodies that are reactive to the central conserved
region of the G protein have been shown to inhibit G protein
CX3C-CX3CR1 interaction, to reduce parameters of RSV
disease including weight loss, pulmonary inflammation, and
lung virus titer [39,40,69,70]. These findings suggest that a
RSV G polypeptide vaccination approach to generate
antibodies reactive to the central conserved region of the G
protein which block G protein CX3C-CX3CR1 interaction may
be an effective strategy in developing safe and effective RSV
vaccines [40]. Additionally, nanoparticle and particulate
vaccines have been shown to induce potent immune
responses in the absence of conventional adjuvants due to the
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Figure 5.  Enumeration of RSV M2-specific CD8+ T cells using MHC class I tetramers.  Spleen and BAL cell suspensions
obtained from mice challenged with RSV A2 were stained with anti-mouse CD3e PE-Cy7-conjugated, anti-mouse CD8α PerCP-
conjugated and APC-labeled M2-specific H-2Kd tetramer. FACS contour plots were gate on CD3/CD8 positive cells. Percentage of
M2- H-2Kd tetramer positive CD8+ T cells in BAL (A and C) and spleen (B) are shown. Error bar represents the SEM from n=5 mice
per group. *, #, p<0.05, significant difference as determined by one-way ANOVA and Dunnett’s test, compared with PBS vaccinated
control mice (*) or compared to live RSV A2 vaccinated mice (#).
doi: 10.1371/journal.pone.0074905.g005
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Figure 6.  Pulmonary cell recruitment and cytokine
production upon RSV infection.  Mice were vaccinated with
50 µg of RSV G nanoparticles, 10 µg of purified G protein
emulsified 1:1 with TiterMAX®, 105 PFU of live RSV A2 or with
100 µL of PBS and challenged at 6 weeks post boost with 106
PFU of RSV A2. BAL were collected at day 5 post challenge
and cell suspensions were immunolabeled with anti-CD3 PE,
anti-CD8 FITC and anti-CD4 PerCPCy5.5 to characterize T
cells (A) or with a combination of anti-CD45 PerCP-Cy5.5, anti-
siglec F PE and anti-CD11c FITC to detect eosinophils (B, grey
bars) and macrophages (B, black bars). Based on cell surface
markers eosinophils were defined as CD45+SiglecF + CD11clow
cells and alveolar macrophages as CD45+SiglecF + CD11chigh
cells. The data are presented as the total number of cells.
Values represent mean ± SEM of cells per BAL (n=5). The
level of IFN-γ, IL-4, IL-5, IL-13, IL-17A and TNF-α (C) were
measured in BAL supernatant by Luminex assay, and the data
are presented as picograms of cytokine/ mL of BAL
supernatant (n=5). *, #, p<0.05, significant difference as
determined by one-way ANOVA and Dunnett’s test, compared
with PBS vaccinated control mice (*) or compared to live RSV
A2 vaccinated mice (#).
doi: 10.1371/journal.pone.0074905.g006
recognition by pathogen recognition receptors on a variety of
cell types [44,46,48,50], thus combining these strategies offer
new vaccine approaches.
In the present study, vaccination with LbL nanoparticle
vaccines comprising the conserved RSV G CX3C motif of RSV
A2, B1, or CH 17 strains was shown to induce neutralizing
antibody responses that inhibit RSV replication upon challenge.
Importantly, the findings from this study also show that
vaccination with RSV B1- and CH 17-derived G protein
nanoparticles induce cross-protection against RSV A2
challenge, a feature important where infection with RSV A
strains may mediate more severe disease symptoms compared
to RSV B stains [71,72], and because both A and B strains may
co-circulate during RSV epidemics [71,72].
Although antibody responses are important for protection
against RSV infection, T cell-mediated responses have an
important role in virus clearance. In this study, mice vaccinated
with RSV G nanoparticles had potent CD8+ T cell responses
and balanced Th1/Th2 responses to RSV challenge. Previous
studies have shown that efficient virus clearance requires Th1-
type responses characterized by IFN-γ, IL-2 and IL-12
expression, and that a bias toward Th2-type responses can
contribute to RSV pulmonary disease characterized by airway
hyperresponsiveness, mucus over-production, wheezing,
bronchiolitis, and pulmonary eosinophilia [33,35,73–75].
Accordingly, increased IL-4 expression and polymorphism in
the IL-4 gene has been correlated with severe RSV lung
disease [76,77] findings consistent with IL-4 mediated
differentiation of CD4+ T cells toward Th2-type cells [78].
Evidence indicates that CD8+ T cells are essential in RSV
clearance [79], and that virus clearance is closely associated
with an increase of RSV-specific CD8+ cytotoxic T cell
recruitment and activity in the lungs [80]. Consistent with these
findings, this study showed an association between RSV G
nanoparticle vaccination-induced cellular responses
characterized by increased IFN-γ and IL-4 secreting cells,
increased frequencies of M2-specific CD8+ T cells, reduced
Th2-type cytokines in BAL fluids, and the outcome of reduced
RSV replication in the lungs of challenged mice.
Of note, this study showed that mice immunized with
nanoparticle vaccines carrying the central conserved region of
the RSV G protein had increased percentages of BAL M2-
specific CD8+ T cells following RSV challenge although none of
the G nanoparticle vaccines contained an RSV M282-90 epitope.
Consistent with our results, it has been previously reported that
in BALB/c mice the RSV G protein, despite lacking H-2d-
restricted epitopes, is critical and enhances the generation of
an effective anti-M282−90 CTL response during RSV infection
[81,82]. In addition, Mei and colleagues have reported that CTL
responses elicited by vaccines carrying the M282−90 epitope
fused to the Measles F protein were greatly enhanced by co-
immunization with a recombinant fragment of G containing the
conserved central region of the protein [83,84]. The mechanism
by which the G protein is enhancing the CTL response to RSV
M2 its unknown, however it is possible that vaccination with
RSV G nanoparticles induces antibodies that block G protein
CX3C-CX3CR1 immune modulatory effects [37,39,40],
specifically G protein interference of pulmonary CD8+ T cell
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recruitment in response to RSV infection [37,38]. Accordingly,
CX3CR1+ CD8+ cells are a major component of the cytotoxic
response to RSV infection, and that infection with an RSV
mutant lacking the G gene dramatically increases the number
of CX3CR1+ T cells in the lungs and reduces Th2-type cytokine
expression [33,75]. Another possible explanation is that RSV G
protein-specific memory CD4+ T cells induced during the
vaccination respond to RSV challenge by expressing Th1-type
cytokines/chemokines that contribute to the increased
activation and proliferation of CD8+ T cells and their
subsequent recruitment to the lungs [82]; however, we did not
see a significant increase in the production of Th1- type
cytokine in BAL fluid of mice vaccinated with G protein
nanoparticles. It is also possible that RSV G and M2 proteins
may share a common T cell epitope, but this is unlikely since
CD4+ and CD8+ T cells from mice vaccinated with RSV G
nanoparticles did not respond to stimulation with M282-90 in the
absence of virus challenge (data not shown). Further study is
required to characterize and understand the role of anti-G
protein immunity on M2-specific CD8+ T cell responses.
Overall, the findings from this study show that RSV challenge
of BALB/c mice vaccinated with RSV G nanoparticle vaccines
is associated with the induction of a neutralizing antibody
response, an increase in RSV G- and M2- specific T cell
responses, and a reduction in pulmonary disease
pathogenesis. Taken together, the findings demonstrate that an
LbL G protein nanoparticle vaccination approach for RSV is
safe and effective in mice, and offers a new strategy in
developing novel RSV vaccines.
Supporting Information
Figure S1.  Antibody responses elicited by vaccination
with RSV G protein nanoparticles and RSV G polypeptides.
Groups of BALB/c mice (n=5) were vaccinated with
polypeptides, polypeptides combined with alum, or nanoparticle
vaccines diluted in PBS to yield 50 µg of designed polypeptide
per dose. RSV A2-specific serum IgG was measured at 21
days after the secondary inoculation. Bars represent the
average titer of each group with error bars representing the
SEM from n=5 mice per group. *, p<0.05, significant difference
as determined by one-way ANOVA and Dunnett’s test.
(TIF)
Figure S2.  Enumeration of RSV M2-specific CD8+ T cells
using MHC class I tetramers. BAL cell suspensions obtained
from mice challenged with RSV A2 were stained with anti-
mouse CD3e PE-Cy7-conjugated, anti-mouse CD8α PerCP-
conjugated and APC-labeled M2-specific H-2Kd tetramer.
FACS contour plots were gate on CD3/CD8 positive cells. Total
numbers of M2- H-2Kd tetramer positive CD8+ T cells are
shown. Error bar represents the SEM from n=5 mice per group.
*, #, p<0.05, significant difference as determined by one-way
ANOVA and Dunnett’s test, compared with PBS vaccinated
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